Our research aims to identify and characterize novel drug targets in acute myeloid leukemia (AML). For this purpose we have established a high-throughput RNAi screening platform to identify novel genes that are required for AML growth. Our candidates are validated and further characterized in patient derived AML cells as well as in AML mouse models by a combination of functional genomic, cell- and molecular biology techniques.

Link to homepage: http://ki.se/ki/jsp/polopoly.jsp?d=41756&l=en